Rebound Weight After GLP-1s: What Studies Show

One of the most consistent — and least comfortable — findings about GLP-1 drugs is what happens when people stop taking them: most regain a substantial share of the weight they lost. This is not a sign that the drugs failed. It is a sign of what they are, and what obesity is. Understanding the rebound reframes the whole conversation from “a course of treatment” to “managing a chronic condition.”

What the studies show

The clearest evidence comes from the STEP 1 trial extension, published by Wilding and colleagues in Diabetes, Obesity and Metabolism in 2022. STEP 1 randomized adults with obesity to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks; the extension then followed 327 participants for another year after all treatment and lifestyle support stopped.

The pattern was striking. Participants on semaglutide had lost 17.3% of body weight by week 68. After stopping, they regained 11.6 percentage points over the next 52 weeks — about two-thirds of what they had lost — leaving a net loss of 5.6% from baseline at week 120. The cardiometabolic improvements (blood pressure, lipids, glycemic markers) reverted in parallel.

The honest summary: in STEP 1’s extension, participants regained two-thirds of their lost weight within a year of stopping semaglutide — going from 17.3% down to a net 5.6% loss. Stopping the drug usually means regaining much of the benefit.

Why the body pushes back

The rebound is not a failure of willpower; it is physiology defending a set point:

• Appetite signals return. The drug’s suppression of hunger and food preoccupation fades as it clears.
• Metabolic adaptation persists. Weight loss lowers energy expenditure, and that adaptation can linger after the drug is gone.
• Hormonal drivers of hunger that were quieted by the medication reassert themselves.

In other words, the underlying biology that produced the weight in the first place is still present. The drug was managing it, not curing it.

What this means for treatment

This reframing has real implications:

1. Obesity behaves like a chronic condition. We do not expect blood pressure to stay low after stopping antihypertensives; the same logic increasingly applies here.
2. Stopping abruptly with no plan tends to fail. Maintenance strategies, lifestyle scaffolding, and in some cases lower maintenance dosing are active areas of study.
3. Expectations should be set honestly up front. Framing these as a short course sets people up for discouragement when the weight returns.

There is ongoing research into whether tapering, intermittent dosing, or pairing the drug with intensive lifestyle support can soften the rebound. The findings are still maturing, and no approach has eliminated regain.

The takeaway

Rebound weight after stopping a GLP-1 is the rule, not the exception, and the STEP 1 extension makes the number concrete: roughly two-thirds of lost weight regained within a year. The cleanest interpretation is not that the drugs do not work — they clearly do while taken — but that obesity is a chronic, biologically defended condition. That makes these medications more like ongoing management than a temporary fix, a framing that is more honest about both their power and their limits.

Sources

• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564
• STEP 1 trial extension — abstract, PubMed